

Government Initiatives To Improve Overall Eye Health Boosts The Anti-Glaucoma Drugs Market

The Business Research Company's Anti-Glaucoma Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026


LONDON, GREATER LONDON, UK, March 16, 2022 /EINPresswire.com/ -- Incidence of glaucoma increases with age and due to increase in the geriatric population worldwide, governments are launching initiatives to promote awareness on glaucoma and other eye disorders. For instance, the Vision

Health initiative by Centers for Disease Control and Prevention (CDC) in the USA aimed to prevent eye disorders including glaucoma and improve the overall eye health. In Australia, the government funded an eye screening program as part of its Vision 2020 initiative to promote awareness and prevent vision loss among the population suffering from glaucoma and other eye disorders. These government initiatives will stimulate the awareness among the people on glaucoma driving the global [antiglaucoma drugs market](#).

According to the antiglaucoma drugs market overview, companies are developing combination therapies in the treatment of glaucoma disease due to their ability to lower intraocular pressure in glaucoma patients. Most of the combination therapies are fixed dose drugs as it offers patient the ease of consumption when compared to non-fixed combinations shaping the [antiglaucoma drugs market outlook](#). Alcon launched a combination drug, Simbrinza which is fixed combination of Brinzolamide and Brimonidine, to help patients in reducing the intake of multiple drugs for glaucoma. Rocklatan is a combination of a rho kinase inhibitor and a prostaglandin analog. Combigan is a combination of beta blocker and alpha agonist. Cosopt is a combination of beta blocker and carbonic anhydrase inhibitor.

Read more on the Global Anti-Glaucoma Drugs Market Report:

<https://www.thebusinessresearchcompany.com/report/antiglaucoma-drugs-global-market-report>



Anti-Glaucoma Drugs Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

The global antiglaucoma drugs market size is expected to grow from \$12.76 billion in 2021 to \$13.91 billion in 2022 at a compound annual growth rate (CAGR) of 9.0%. The growth in the market is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The global anti-glaucoma drugs market size is expected to reach \$18.62 billion in 2026 at a CAGR of 7.6%.

Major players covered in the global anti-glaucoma drugs industry are Aerie Pharmaceuticals, Inc., Allergan, Novartis AG, Abbott Healthcare, Johnson & Johnson, Merck & Co, Genentech Inc., Pfizer, Inc., Bayer AG and Santen Pharmaceuticals Company Ltd.

North America is the largest region in the antiglaucoma drugs market in 2021. The Middle East is expected to be the fastest growing region in the global antiglaucoma drug market during the forecast period. The regions covered in the global anti-glaucoma drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

TBRC's global antiglaucoma drugs market report is segmented by product type into alpha agonist, beta blockers, prostaglandin analogs, combined medication, others, by disease condition type into open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, congenital glaucoma, others, by type into hospital prescription drugs, over-the-counter drugs.

Antiglaucoma Drugs Global Market Report 2022 – By Product Type (Alpha Agonist, Beta Blockers, Prostaglandin Analogs, Combined Medication), By Disease Condition Type (Open-Angle Glaucoma, Angle-Closure Glaucoma, Normal-Tension Glaucoma, Congenital Glaucoma, Other Types Of Glaucoma), By Type (Hospital Prescription drugs, Over-the counter drugs) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a anti-glaucoma drugs market overview, anti-glaucoma drugs market forecast, anti-glaucoma drugs market size and anti-glaucoma drugs market growth for the whole anti-glaucoma drugs market, anti-glaucoma drugs market segments, anti-glaucoma drugs market geographies, anti-glaucoma drugs market trends, anti-glaucoma drugs market drivers, anti-glaucoma drugs market restraints, leading competitors' anti-glaucoma drugs market revenues, anti-glaucoma drugs market profiles, and anti-glaucoma drugs market shares.

Request for a Sample of the Global Anti-Glaucoma Drugs Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=3803&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Diagnostic And Monitoring Ophthalmic Devices And Equipment Global Market Report 2021 - By

Product Type (Optical Coherence Tomographers, Ophthalmic Ultrasound Imaging Systems, Fundus Cameras, Ophthalmoscopes, Keratometers, Specular Microscopes, Tonometers, Slit Lamps, Retinoscopes), By End User (Hospitals, Clinics, Diagnostic Laboratories, Research Centers), By Application (Retinal Evaluation, Glaucoma Detection and Monitoring, Surgical Evaluation, General Examination, Intraoperative Devices, Refraction Equipment), COVID-19 Impact And Recovery

<https://www.thebusinessresearchcompany.com/report/diagnostic-and-monitoring-ophthalmic-devices-and-equipment-global-market-report>

Diuretics Global Market Report 2022 – By Type (Osmotic Diuretics, Carbonic Anhydrase Inhibitors, Loop Diuretics, Thiazides & Thiazide-Like Diuretics, Aldosterone Antagonists), By Application (Hypertension, Glaucoma, Heart Failure, Kidney Stones), By Distribution (Hospital Pharmacies, Independent Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies), By Route of Administration (Intravenous, Oral) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/diuretics-drugs-global-market-report>

HP (High Potency) APIs Global Market Report 2022 – By Type (Innovative HPAPI, Generic HPAPI), By Synthesis Type (Synthetic HPAPI, Biotech HPAPI), By Therapeutic Application (Oncology, Hormonal Disorder, Glaucoma, Other Therapeutic Applications (Respiratory Disorders, CVD, Diabetes, Cosmetology, And Erectile Dysfunction)) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/hp-high-potency-api-global-market-report>

About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/565666194>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.